EcoDrugPlus

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSLLTG00000005385
Gene Symbol: AVPR1A
1 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSLLTG00000014909
Gene Symbol: AVPR1B
1 Cross references
135 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Arginine Vasopressin Receptor 2

Ensembl ID : ENSLLTG00000005132
Gene Symbol: AVPR2
1 Cross references
231 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aurora Kinase A

Ensembl ID : ENSLLTG00000001531
Gene Symbol: AURKA
1 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aurora Kinase B

Ensembl ID : ENSLLTG00000000624
Gene Symbol: AURKB
1 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Beta-Secretase 1

Ensembl ID : ENSLLTG00000011940
Gene Symbol: BACE1
1 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bradykinin Receptor B2

Ensembl ID : ENSLLTG00000014289
Gene Symbol: BDKRB2
1 Cross references
356 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Butyrylcholinesterase

Ensembl ID : ENSLLTG00000016729
Gene Symbol: BCHE
1 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSLLTG00000003415
Gene Symbol: CACNB2
1 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSLLTG00000014112
Gene Symbol: CACNB3
1 Cross references
125 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSLLTG00000015299
Gene Symbol: CACNG2
1 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 3

Ensembl ID : ENSLLTG00000003267
Gene Symbol: CACNG3
1 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).